SLC17A8

Across TCGA pan-cancer cohorts, SLC17A8 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SLC17A8 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher SLC17A8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC17A8 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

BRCA, UCEC, and LIHC are the cancer types where SLC17A8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.114	0.579	<.001	22	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	OS	Median	All	0.098	0.774	.001	6	view →
BLCA	OS	Median	All	0.188	0.687	.020	6	view →
SARC	DFS	Median	All	0.127	0.611	.049	3	view →
LUAD	DFS	Median	All	1.000	0.658	.036	2	view →
SKCM	OS	Median	III,IV	0.359	0.734	.008	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SLC17A8–BRCA (OS)

Open the BRCA breakdown →